Epidemiological data indicate that 20-40% of the patients with epilepsy are refractory to treatment with antiepileptic drugs (AEDs). The mechanisms underlying pharmacoresistance in epilepsy are unclear, but several plausible hypotheses have emerged, including loss of AED target sensitivity in the epileptic brain, decreased AED concentrations at brain targets because of localized overexpression of drug efflux transporters in epileptogenic brain tissue, and network alterations in response to brain damage associated with epilepsy. Rat models of epilepsy in which part of the animals are resistant to treatment with AEDs offer a means to investigate the mechanisms underlying AED resistance. In the present study, AEDresponsive and AED-resistant rats were selected from a model in which spontaneous recurrent seizures develop after a status epilepticus induced by electrical stimulation of the basolateral amygdala. For selection into responders and nonresponders, epileptic rats were treated over two weeks by phenobarbital. Subsequent histological examination showed neurodegeneration of the CA1, CA3 and dentate hilus in only one of eight responders but five of six nonresponders (P = 0.0256). Based on previous studies in AED-resistant rats of this model, we hypothesized that changes in the structure and function of inhibitory GABA A receptors may contribute to drug resistance. We therefore analyzed the distribution and expression of several GABA A receptor subunits (α1, α2, α3, α4, α5, β2/3, and γ2) immunohistochemically with specific antibodies in the hippocampal formation of responders, nonresponders and nonepileptic controls. In nonresponders, decreased subunit staining was observed in CA1, CA2, CA3, and dentate gyrus, whereas much less widespread alterations were determined in responders. Furthermore, upregulation of the α4-subunit was observed in the CA1 of nonresponders. Our data suggest that alterations in GABA A receptor subtypes may be involved in resistance to AEDs.
Introduction
Epilepsy is one of the most common serious brain disorders, and is associated with an increased risk of comorbidities and mortality (Chang and Lowenstein, 2003) . Despite the availability of various newly developed antiepileptic drugs (AEDs), pharmacoresistance remains a major challenge in epilepsy management (Schmidt and Löscher, 2005) . Unravelling the mechanisms underlying AED resistance has been the focus of intense efforts to develop new rationally designed therapies for as yet refractory epilepsies. Based on experimental and clinical studies, two major neurobiological theories have been put forward: (a) the multidrug transporter hypothesis, which suggests that increased brain expression of drug efflux transporters such as P-glycoprotein (P-gp) decreases AED levels at their brain targets, and (b) the target hypothesis, which suggests that AEDs are not effective because of target alterations in epileptogenic brain tissue (Löscher and Potschka, 2005; Remy and Beck, 2006) . Most AEDs exert their effects either by modulation of voltage-dependent ion channels or by enhancing the inhibitory action of GABA (Rogawski and Löscher, 2004) . There is some evidence that resistance to Na + channel modulators such as carbamazepine may be due to target alterations in epileptogenic tissue of patients with refractory epilepsy (Remy and Beck, 2006) . However, as yet no such clinical evidence is available for other AED targets such as GABA A receptors.
Animal models of epilepsy provide a means to investigate fundamental mechanisms underlying the development of epilepsy and AED resistance in epilepsy (Löscher, 2006) . Combined molecular and functional studies in rat models of temporal lobe epilepsy (TLE) indicate a transcriptionally mediated switch in the alpha subunit composition of GABA A receptors in the hippocampal formation, characterized by a decrease of α1 subunits and an increase of α4 subunits in epileptic animals compared to controls (Brooks-Kayal et al., 1998; Coulter, 2000) . This switch in the alpha subunit composition is associated with a reduced in vitro sensitivity to AEDs acting on the benzodiazepine site of the GABA A receptor (Coulter, 2001 ). However, none of these studies evaluated whether these changes in the GABA A receptor subunit expression in the hippocampus of epileptic 
